Latest PEGylation Stories
SAN DIEGO, Aug. 2, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report second quarter 2011 financial results on Monday, August 8, 2011, after the U.S.
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients. Over 600 patients who have failed prior systemic therapy will be enrolled in the randomized, double-blind, placebo-controlled study at sites in China, Taiwan, the United States, Italy and the U.K..
NES-ZIONA, Israel, July 11, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that it has received a notice of allowance from the U.S.
-- Sigma-Tau Pharmaceuticals, Inc. Announces Co-Pay Program for OncasparÂ® (pegaspargase) -- GAITHERSBURG, Md., June 27, 2011 /PRNewswire-USNewswire/ -- Today, Sigma-Tau Pharmaceuticals, Inc. announced a vital new service for people with Acute Lymphoblastic Leukemia (ALL).
NES-ZIONA, Israel, June 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that the U.S. Patent and Trademark Office (PTO) has allowed a new patent for the company's veterinary version of its long-acting CTP-enhanced non-human growth hormone (NhGH-CTP).
NES-ZIONA, Israel, June 6, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG).
NES-ZIONA, Israel, May 31, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Jefferies 2011 Global Healthcare Conference on June 6, 2011 at 9:30 AM ET. A live webcast of the company's presentation will be available in the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=215, or at the...
Vertex Pharmaceuticals Inc's highly anticipated hepatitis C drug has finally won US approval, which will usher in a new marketing battle with a rival medicine from Merck & Co.
NES-ZIONA, Israel, May 23, 2011 /PRNewswire/ -- PROLOR Biotech, Inc.
- Withering but not falling off, as a blossom that persists on a twig after flowering.